The FDA’s Division of Drug Marketing, Advertising and Communications has issued untitled letters of violation to Schering-Plough for its Nasonex nasal spray, and to GlaxoSmithKline for its Flonase ...
Schering-Plough's successful allergy medication gets an updated ad campaign. The Nasonex Bee is buzzing a new tune. Schering-Plough is working with BBDO to update its successful Nasonex (mometasone ...
Bear Stearns maintained an "underperform" rating on Schering-Plough and said a federal judge's refusal to block sales of generic allergy drug Flonase increases "substitution risk" for the company's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results